Should Low-Molecular-Weight Heparin be Preferred Over Unfractionated Heparin After Thrombolysis for Severity Pulmonary Embolism?

Basit Öğe Kaydı
dc.contributor.authorSenturk, Aysegul
dc.contributor.authorUcar, Elif Yilmazel
dc.contributor.authorBerk, Serdar
dc.contributor.authorOzlu, Tevfik
dc.contributor.authorAltinsoy, Bulent
dc.contributor.authorDabak, Gul
dc.contributor.authorCakir, Ebru
dc.date.accessioned2024-04-24T17:14:39Z
dc.date.available2024-04-24T17:14:39Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: The role of low-molecular-weight heparin (LMWH) in managing nonmassive pulmonary embolism (PE) is well known. In unstable cases, especially after thrombolytic therapy for massive PE, unfractionated heparin (UFH) is preferred for PE management. This study aimed to investigate the effectiveness and safety of LMWH after thrombolytic therapy. Methods: A prospective, observational multicenter trial was performed in 249 patients with acute PE who required thrombolysis. Massive and submassive PEs were categorized into 2 groups depending on whether they were treated with LMWH or UFH after thrombolytic treatment. The primary end point was all-cause mortality during the first 30 days; the secondary end point included all-cause mortality, nonfatal symptomatic recurrent PEs, or nonfatal major bleeding. Results: The mean age at diagnosis was 60.7 15.5 years. The PE severity was massive in 186 (74.7%) patients and submassive in 63 (25.3%). The incidence of all-cause 30-day death was 8.2% and 17.3% in patients with LMWH and UFH, respectively (P = .031). Major hemorrhage occurred in 4% (n = 5) and 7.9% (n = 10) of patients and minor hemorrhage occurred in 9% (n = 11) and 13.4% (n = 17) of the cases treated with LMWH and UFH, respectively. Conclusion: These results suggest that LMWH treatment can be used safely in patients with PE after thrombolytic therapy.en_US
dc.identifier.doi10.1177/1076029614564863
dc.identifier.endpage399en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue4en_US
dc.identifier.pmid25630985
dc.identifier.scopus2-s2.0-84962349245
dc.identifier.scopusqualityQ2
dc.identifier.startpage395en_US
dc.identifier.urihttps://doi.org/10.1177/1076029614564863
dc.identifier.urihttps://hdl.handle.net/11468/18124
dc.identifier.volume22en_US
dc.identifier.wosWOS:000373916700015
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical and Applied Thrombosis-Hemostasis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPulmonary Thromboembolismen_US
dc.subjectLow-Molecular-Weight Heparinen_US
dc.subjectUnfractionated Heparinen_US
dc.titleShould Low-Molecular-Weight Heparin be Preferred Over Unfractionated Heparin After Thrombolysis for Severity Pulmonary Embolism?en_US
dc.titleShould Low-Molecular-Weight Heparin be Preferred Over Unfractionated Heparin After Thrombolysis for Severity Pulmonary Embolism?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu